Article

A data driven approach to identify ZM-447439 as a potential repurposed drug to overcome tamoxifen-resistance in breast cancer

2020-08-21

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Tamoxifen is the most commonly used endocrine therapy (ET) for Breast Cancer (BC) patients expressing estrogen receptors (ER), representing almost 70% of all cases. However, one third of early stage BC patients demonstrate endocrine resistance to tamoxifen over the initial five-year treatment period, prompting significant research effort on identifying other dru...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6ae3f76f-1bb1-5137-b3fd-306743cc140b
DOI: 10.21203/rs.3.rs-56103/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A data driven approach to identify ZM-447439 as a potential repurposed drug to overcome tamoxifen-resistance in breast cancerDOI 10.21203/rs.3.rs-56103/v1Read

Exploring Drug-Target Interactions through Network Pharmacology in Breast cancer: A Text Mining ApproachSemantic proximity Read

An “Omics” Approach to Determine the Mechanisms of Acquired Aromatase Inhibitor ResistanceSemantic proximity Read

Drug Repositioning Study in Search of Potent Inhibitors Blocking Multiple Pathways for the Treatment of Breast CancerSemantic proximity Read

Computationally repurposing drugs for breast cancer subtypes using a network-based approachSemantic proximity Read

Identification of Significant Genes and Therapeutic Agents for Breast Cancer by Integrated BioinformaticsSemantic proximity Read

BC-Predict Database: A Curated Resource of Experimentally Validated Markers in Multidrug Resistance in Breast CancerSemantic proximity Read

A Novel Approach to Classifying Chemotherapeutic Agents Based on Their Impact on Canonical Pathways: Implications for Overcoming Multidrug Resistance in Breast CancerSemantic proximity Read

Computationally Repurposing Drugs for Breast Cancer Subtypes Using a Network-Based ApproachSemantic proximity Read

Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of ActionSemantic proximity Read

Investigation of the Genomic and Transcriptomic Variations Underlying Tamoxifen Resistance in Breast CancerSemantic proximity Read

RRM2 as a Key Biomarker and Therapeutic Target in Letrozole-Resistant ER+ Breast Cancer: Insights from Bioinformatics and Molecular DockingSemantic proximity Read

New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistanceSemantic proximity Read